Business
LENZ Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the
About this update from Lenz Therapeutics, Inc.
SAN DIEGO , Nov. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences: Piper Sandler 37 th Annual Healthcare Conference Date: December 2, 2025 Location: New York City , NY Format: Fireside chat at 3:30pm ET (live audio webcast ) and 1x1 investor meetings 8 th Annual Evercore Healthcare Conference Date: December 3, 2025 Location: Coral Gables, FL Format: Fireside chat at 1:20pm ET (live audio webcast ) and 1x1 investor meetings Citi’s 2025 Global Healthcare Conference Date: December 4, 2025 Location: Miami, FL Format: Fireside chat at 10:30am ET (live audio webcast ) and 1x1 investor meetings Live audio webcasts will also be available on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcasts will be available on the Company’s website for 12 months following the event. About LENZ Therapeutics LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZTM (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States . LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California . For more information, visit www.VIZZ.com and www.LENZ-tx.com . Contacts: Dan Chevallard LENZ Therapeutics [email protected] Source: LENZ Therapeutics, Inc.
View stock analysis, news, and events for Lenz Therapeutics, Inc.